Avadel Pharmaceuticals (AVDL) Scheduled to Post Quarterly Earnings on Thursday

Avadel Pharmaceuticals (NASDAQ:AVDL) is set to issue its quarterly earnings data before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Avadel Pharmaceuticals (NASDAQ:AVDL) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.05). Avadel Pharmaceuticals had a negative net margin of 284.42% and a negative return on equity of 139.72%. The company had revenue of $27.18 million during the quarter, compared to the consensus estimate of $25.89 million. During the same quarter in the previous year, the firm posted ($0.48) EPS. The business’s revenue for the quarter was up 2617.8% compared to the same quarter last year. On average, analysts expect Avadel Pharmaceuticals to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Avadel Pharmaceuticals Stock Up 3.0 %

Shares of Avadel Pharmaceuticals stock traded up $0.48 on Tuesday, hitting $16.61. The stock had a trading volume of 376,629 shares, compared to its average volume of 1,231,819. Avadel Pharmaceuticals has a one year low of $9.50 and a one year high of $19.09. The stock’s 50-day simple moving average is $15.57 and its two-hundred day simple moving average is $15.70. The stock has a market cap of $1.60 billion, a price-to-earnings ratio of -8.67 and a beta of 1.53.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on AVDL. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Avadel Pharmaceuticals in a report on Wednesday, May 8th. Craig Hallum lifted their price objective on Avadel Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. HC Wainwright upped their target price on Avadel Pharmaceuticals from $25.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, May 9th. Finally, Rodman & Renshaw assumed coverage on Avadel Pharmaceuticals in a research note on Wednesday, June 12th. They issued a “buy” rating and a $27.00 price target for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $24.57.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.